Potential benefits of neoadjuvant therapy for locally advanced @entity356 include @entity5 downstaging and an increased R0 resection rate. Potential disadvantages include @entity455 . This study assesses postoperative morbidity and mortality by comparing @entity1 undergoing gastrectomy with and without neoadjuvant chemotherapy. From October 1998 to July 2002, a total of 34 @entity1 with locally advanced @entity356 were placed on a phase II neoadjuvant chemotherapy protocol consisting of two cycles of @entity2600 (75 mg/m(2)) with @entity900 (25 mg/m(2)). Demographic, clinical, morbidity, and mortality data were compared for these @entity1 (CHEMO) versus 85 @entity1 undergoing gastrectomy without neoadjuvant chemotherapy (SURG). The CHEMO @entity1 were more likely to be less than 70 years of age (P< or =0.01), have proximal @entity5 (P< or =0.01), and undergo proximal gastrectomy (P< or =0.025). Fifty-two percent of SURG @entity1 had T3/T4 @entity5 compared to 19% of CHEMO @entity1 , consistent with @entity5 downstaging. The R0 resection rate was similar (80%). Morbidity was 41% in CHEMO @entity1 and 39% in SURG @entity1 . There were five postoperative deaths (4.4%), two in the CHEMO group and three in the SURG group (P=NS). It was concluded that neoadjuvant chemotherapy with @entity2600 and @entity900 is not associated with increased postoperative morbidity compared to surgery alone. @entity2600 -based neoadjuvant chemotherapy should be tested further in combined-modality treatment of @entity356 .

Complications of gastrectomy following @entity2600 -based neoadjuvant chemotherapy for XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity455 :: ('MESH:D014652', 'Disease') :: ['increased surgical complications'] @entity2600 :: ('MESH:C051890', 'Chemical') :: ['CPT-11'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer']
@entity356 :: (MESH:D013274,Disease) :: ['gastric cancer']
